Corporate Website
Africa
Argentina
Asia
Australia
Belgium
Brazil
Bulgaria
Canada (EN)
Chile
China
Colombia
Denmark
Egypt
France
Germany
Greece
Hungary
Indonesia
Italia
India
Japan
Korea
Malaysia
Mexico
Middle East
Netherlands
Peru
Philippines
Poland
Portugal
Romania
Russia
South Africa
Spain
Sweden
Thailand
Tunisia
Turkey
Ukraine
United Kingdom
USA
Vietnam
Your search for "innovation" return 116 results.
Ceva expands oral rabies vaccine portfolio with the acquisition of Canadian firm Artemis Technologies, Inc. >
This strategic acquisition complements Ceva’s rabies portfolio.
Ceva celebrates 100 years of developing animal vaccines at its Dessau site in Germany >
A century of significant contributions to animal health
Ceva partners with Liryc, the global leading institute in heart rhythm disorders >
The objective: to promote One Health platform of excellence dedicated to cardiology, stimulating research and medical innovation at the interface between humans and companion animals.
Ceva invests in its European vaccine production capacity to create the EU’s largest cryogenic storage facility in Monor >
The new site is situated in Monor, 40kms from the centre of Budapest.
Ceva’s QTest validated as an effective and practical way to diagnose Q fever in dairy herds worldwide >
This tool offers a breakthrough innovation to farmers and veterinarians, by making the diagnosis easier.
PREVENT project to boost prospects for 150,000 backyard poultry producers in Africa >
With Africa’s population set to double, new technologies, including improved poultry vaccination, will be necessary to provide enough affordable, quality protein.
Research and innovation in animal health: a strengthened partnership between INRAE and Ceva Santé Animale >
A shared commitment to the "One Health" global health concept
Ceva builds on its preventative health strategy with opening of a new European reference for the manufacture of autogenous vaccines >
An innovative project confirms Ceva’s commitment to improving preventative animal health and reducing the use of antibiotics.
Ceva returns to strong double-digit growth in 2019 and reveals plans to double sales by 2025 >
Libourne, 12 March 2020 - Consolidated sales of the Ceva Group reached more than €1.2 billion in 2019 as the company returned to strong double-digit growth (+14.6%). The start of 2020 was marked by t...
Ceva reorganizes its shareholding structure welcoming new long-term partners alongside existing investors to secure the group’s independent future. >
Libourne, 4 February 2020: Ceva Santé Animale today announced that it has renewed its shareholding structure, welcoming leading international investors to join long-term partners, who will invest alon...